Search

Displaying results 3401 - 3410 of 8196 in total
  1. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

  2. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC).

  3. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side

  4. Drug

    Sulbactam pivoxil

    go.drugbank.com/drugs/DB15761
    Investigational

    Mixtures: EUMOXIN DUO FORTE, EUMOXIN® DUO FORTE
  5. Target

    Relaxin receptor 2

    go.drugbank.com/bio_entities/BE0017729
    TargetHumans

    Receptor for relaxin. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. May also be a receptor for Leydig insulin-like peptide (INSL3)

    Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 8
  6. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  7. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  8. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. … The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  9. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors